- KalVista Pharmaceuticals (NASDAQ:KALV) announces clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop.
- An analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity in Phase 2 cross-over trial in patients with HAE type I and II is as follows:
- KVD900 achieves rapid plasma exposures, with near complete plasma kallikrein inhibition within 30 minutes.
- A 50% reduction in the composite VAS was reached for 50% of the attacks treated with KVD900 within six hours vs. greater than 12 hours for attacks treated with placebo.
- By 24 hours, 74% of KVD900-treated attacks showed a 50% reduction in score compared to 38% for placebo-treated attacks.
- Adverse events were of mild or moderate intensity with no severe or serious adverse events reported. Overall, the single administration of KVD900 appeared safe and well tolerated.